PT896534E - Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino - Google Patents

Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino

Info

Publication number
PT896534E
PT896534E PT97916406T PT97916406T PT896534E PT 896534 E PT896534 E PT 896534E PT 97916406 T PT97916406 T PT 97916406T PT 97916406 T PT97916406 T PT 97916406T PT 896534 E PT896534 E PT 896534E
Authority
PT
Portugal
Prior art keywords
avermectins
formulations
milbemicines
injection
pct
Prior art date
Application number
PT97916406T
Other languages
English (en)
Inventor
Michael Grosse-Bley
Kujanek Richard
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT896534(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PT896534E publication Critical patent/PT896534E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PT97916406T 1996-04-09 1997-03-27 Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino PT896534E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19613972A DE19613972A1 (de) 1996-04-09 1996-04-09 Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl

Publications (1)

Publication Number Publication Date
PT896534E true PT896534E (pt) 2005-04-29

Family

ID=7790774

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97916406T PT896534E (pt) 1996-04-09 1997-03-27 Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino

Country Status (14)

Country Link
US (1) US6063394A (pt)
EP (1) EP0896534B1 (pt)
JP (1) JP4257870B2 (pt)
CN (1) CN1095662C (pt)
AT (1) ATE285233T1 (pt)
AU (1) AU718807B2 (pt)
BR (1) BR9708540B1 (pt)
CA (1) CA2251087C (pt)
DE (2) DE19613972A1 (pt)
ES (1) ES2235230T3 (pt)
HK (1) HK1019404A1 (pt)
NZ (1) NZ332224A (pt)
PT (1) PT896534E (pt)
WO (1) WO1997037653A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19638045A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
DE69818093T2 (de) * 1997-12-03 2004-06-09 Merck & Co., Inc. Langwirkende, injizierbare, formulierungen enthaltend rizinusöl
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
GB9827727D0 (en) * 1998-12-16 1999-02-10 Pfizer Ltd Antiparasitic formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
AU781682B2 (en) * 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
US20050009762A1 (en) * 2003-06-06 2005-01-13 Strobel Michael Albert Application of water and organic solvent soluble ivermectin for topical and oral use
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
US7262214B2 (en) 2003-02-26 2007-08-28 Merial Limited 1-N-arylpyrazole derivatives in prevention of arthropod-borne and mosquito-borne diseases
US20050271459A1 (en) * 2004-06-03 2005-12-08 World Wide Stationery Mfg. Co., Ltd. Interlocking ring tip formations for paired ring members of a ring binder mechanism
NZ534939A (en) * 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
DE102004053964A1 (de) * 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
WO2009027697A2 (en) * 2007-08-31 2009-03-05 Archimedes Development Limited Non-aqueous pharmaceutical compositions
US20100022469A1 (en) * 2008-06-24 2010-01-28 Majid Razzak Anthelminthic formulations
CN102316876B (zh) 2009-02-16 2013-07-17 佐蒂斯有限责任公司 高剂量多拉菌素制剂
CN101773467B (zh) * 2010-01-20 2015-09-09 北京大北农动物保健科技有限责任公司 一种美贝霉素或美贝霉素肟的兽用缓释注射液及制备方法
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
WO2013137748A1 (en) * 2012-03-13 2013-09-19 Bayer New Zealand Limited Long acting compositions
BR112020012018A2 (pt) 2017-12-15 2020-11-24 Tarsus Pharmaceuticals, Inc. formulações de parasiticida de isoxazolina e métodos para tratar blefarite
AR118215A1 (es) * 2019-03-01 2021-09-22 Boehringer Ingelheim Animal Health Usa Inc Composiciones inyectables de clorsulón, sus métodos y usos
US11077134B1 (en) 2020-11-10 2021-08-03 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
US11638714B2 (en) 2020-11-10 2023-05-02 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
CN114642632A (zh) * 2022-02-25 2022-06-21 河北科技大学 一种莫西克汀注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4914624A (pt) * 1972-06-08 1974-02-08
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
NZ197796A (en) * 1980-08-04 1984-11-09 Merck & Co Inc Stabilised aqueous formulations containing ivermectin
NZ210505A (en) * 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
DE3727648A1 (de) * 1987-08-19 1989-03-02 Bayer Ag Neue avermectin derivate, verfahren zu ihrer herstellung und ihre verwendung
US5510117A (en) * 1989-03-09 1996-04-23 Micro-Pak, Inc. Entrapment vehicle and method
EP0393890B1 (en) * 1989-04-11 1992-08-12 Pfizer Limited Injectable compositions containing 25-cyclohexyl-avermectin b1
NZ234802A (en) * 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
ES2086022T3 (es) * 1991-07-23 1996-06-16 American Cyanamid Co Composiciones estables para administracion parenteral y su uso.
ATE180671T1 (de) * 1991-09-30 1999-06-15 Merck & Co Inc Hydrierte rizinusöl-enthaltende injizierbare formulierungen mit verlängerter wirkstoffabgabe
WO1994008566A1 (en) * 1992-10-21 1994-04-28 Micro Vesicular Systems, Inc. Entrapment vehicle and method

Also Published As

Publication number Publication date
JP4257870B2 (ja) 2009-04-22
CN1095662C (zh) 2002-12-11
US6063394A (en) 2000-05-16
AU718807B2 (en) 2000-04-20
WO1997037653A1 (de) 1997-10-16
BR9708540B1 (pt) 2010-07-27
HK1019404A1 (en) 2000-02-11
AU2506697A (en) 1997-10-29
CA2251087C (en) 2008-01-15
EP0896534B1 (de) 2004-12-22
DE59712134D1 (de) 2005-01-27
JP2000508301A (ja) 2000-07-04
NZ332224A (en) 2000-06-23
CA2251087A1 (en) 1997-10-16
DE19613972A1 (de) 1997-10-16
ES2235230T3 (es) 2005-07-01
EP0896534A1 (de) 1999-02-17
ATE285233T1 (de) 2005-01-15
CN1215331A (zh) 1999-04-28
BR9708540A (pt) 1999-08-03

Similar Documents

Publication Publication Date Title
PT896534E (pt) Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino
DE59706898D1 (de) Feste geschäumte wirkstoffzubereitungen
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
BR9707834A (pt) Uso de conservante de madeira, e, bandagem para pós-proteção de madeira
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
AU4047297A (en) Synchronization of server database with client database using distribution tables
AU3897197A (en) Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
AU3541697A (en) Use of artichoke (cynara) extracts
IL122737A0 (en) Salts of amidine derivative and cyclooxygenase inhibitors their preparation and pharmaceutical compositions containing them
BR9712058A (pt) Formula-{es para ine-Æo de avermectinas e milbemicinas
AR016981A2 (es) Polipeptidos sinteticos
AU4088097A (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans
NO20000107L (no) Ny blanding
DE69818988D1 (de) 9,10-diazatryclo[4.2.11 2,5]decan- und 9,10-diazatricyclo[3.3.1.1 2,6]decanderive mit analgetischer wirkung
ES2165020T3 (es) Monohidrato de famciclovir.
BR7901395U (pt) Personalização de cadeiras de escritório e método para personalização de cadeiras de escritório
DK0896534T3 (da) Injektionsformuleringer af avermectiner og milbemyciner på basis af ricinusolie
HUP9903596A3 (en) Injection formulations of avermectins and milbemycins based on castor oil
BR7600808U (pt) Mesa para escritório
ECSP982723A (es) 1, 2, 4 triazolo [3, 4-a] piridazina sustituida
ES1034076Y (es) Pata perfeccionada, para mobiliario de oficina.
UA32595C2 (uk) Антиоксидант для туалетного мила
BR7600022U (pt) Mesa para jogo de bingo vispora e tômbola
ES1040365Y (es) Armadura para mobiliario de oficina y similar.
ES1034726Y (es) Mueble expositor para piezas ceramicas.